Sglt 2i CKD Farxiga denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Farxiga for CKD as "Experimental" — and How to Appeal

An "experimental or investigational" denial for Farxiga (dapagliflozin) in the context of chronic kidney disease is one of the most rebuttable denials in this class. Dapagliflozin holds a specific FDA approval for reducing the risk of sustained decline in kidney function and kidney failure in adults with CKD. FDA approval is the standard legal threshold that distinguishes an established therapy from an experimental one — and dapagliflozin has cleared that threshold for this indication.

This type of denial most commonly occurs because Cigna's review system applied a coverage policy that was drafted before the FDA approved the CKD indication, has not been updated to reflect it, or was applied in error to a different formulation or off-label use. It may also reflect a reviewer's unfamiliarity with the specific approved indication.

### Why This Denial Is Frequently Overturned

Appeals grounded in an FDA approval with supporting major guideline endorsement have a high success rate at the external-review stage. Independent review organizations apply objective criteria — primarily FDA approval status and recognized clinical-guideline support — rather than internal plan policy. Dapagliflozin's CKD indication is supported by major nephrology and cardiology guideline organizations. Confirm the current guideline language from the relevant professional society (such as the applicable KDIGO or ACC/AHA guideline) and cite the organization by name in your appeal without quoting specific numerical thresholds.

### Federal Appeal Framework

• Internal appeal (ACA / ERISA §503): File within the deadline on your denial letter. Request that a clinical reviewer with nephrology expertise review the appeal — you have the right to a reviewer not involved in the original denial.
• External review (ACA §2719): A final internal denial triggers the right to independent external review. File within approximately four months. The external reviewer's decision is binding.
• Expedited review: Available if delay threatens health. Request it in writing simultaneously with the standard appeal.

### Concrete Appeal Steps and Timeline

1. Obtain the denial letter and identify the exact policy language Cigna used to classify the drug as experimental. 2. Download and print the current FDA-approved prescribing information for Farxiga. Highlight the CKD indication in the "Indications and Usage" section — this is your primary rebuttal exhibit. 3. Locate the current version of the relevant clinical practice guideline that includes dapagliflozin recommendations for CKD (ask your prescriber or nephrologist to identify it). 4. Obtain Cigna's published coverage policy for SGLT2 inhibitors in CKD. If the policy predates the FDA approval, document that gap explicitly. 5. Have your prescriber write a letter stating the FDA-approved indication, citing the guideline, and explaining the patient's clinical profile. 6. File the internal appeal. If denied, file for external review immediately.

### Documentation to Gather

• FDA prescribing label for Farxiga with CKD indication highlighted.
• Cigna's coverage policy and its effective/revision date.
• Diagnosis and staging records: Chart notes confirming CKD diagnosis and clinical course.
• Guideline reference: A printed or linked copy of the relevant professional society guideline supporting dapagliflozin in CKD.
• Prescriber medical-necessity letter: Explicitly addresses the FDA-approval status and refutes the experimental classification.

### Criteria-Mapping Structure

For each element of Cigna's experimental-denial criteria, provide a direct written rebuttal. Pair every policy requirement with the specific document that satisfies or refutes it. If the policy was not updated to reflect the FDA approval, say so explicitly and attach the dated FDA label.